BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial
PEI supports BiondVax's plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby...